Abstract N-myc downstream-regulated gene 2 (NDRG2) is a differentiation-and stress-associated molecule that is predominantly expressed in astrocytes in the central nervous system. In this study, we examined the expression and role of NDRG2 in experimental autoimmune encephalomyelitis (EAE), which is an animal model of multiple sclerosis. Western blot and immunohistochemical analysis revealed that the expression of NDRG2 was observed in astrocytes of spinal cord, and was enhanced after EAE induction. A comparative analysis of wild-type and Ndrg2 À/À mice revealed that deletion of Ndrg2 ameliorated the clinical symptoms of EAE. Although Ndrg2 deficiency only slightly affected the inflammatory response, based on the results of flow cytometry, qRT-PCR, and immunohistochemistry, it significantly reduced demyelination in the chronic phase, and, more importantly, neurodegeneration both in the acute and chronic phases. Further studies revealed that the expression of astrocytic glutamate transporters, including glutamate aspartate transporter (GLAST) and glutamate transporter 1, was more maintained in the Ndrg2 À/À mice compared with wild-type mice after EAE induction. Consistent with these results, studies using cultured astrocytes revealed that Ndrg2 gene silencing increased the expression of GLAST, while NDRG2 over-expression decreased it without altering the expression of glial fibrillary acidic protein. The effect of NDRG2 on GLAST expression was associated with the activation of Akt, but not with the activation of nuclear factor-kappa B. These findings suggest that NDRG2 plays a key role in the pathology of EAE by modulating glutamate metabolism.
Multiple sclerosis (MS), which is the most common autoimmune disease of the central nervous system (CNS), affects approximately 2.5 million people worldwide (Compston et al. 2008) . Both MS and its well-studied murine model, experimental autoimmune encephalomyelitis (EAE), are characterized by the infiltration of activated autoreactive myelin-specific CD4 + T cells into the CNS, which results in inflammation, demyelination, and neurodegeneration (Dendrou et al. 2015) . However, accumulating evidence suggests that a broader range of CNS cells including glial cells contribute to the development of MS/EAE pathology (Duffy et al. 2014) . Among these, activated microglia, which produce a plethora of neurotoxic inflammatory mediators, such as cytokines, chemokines, and reactive oxygen species are now considered key players in MS/EAE pathogenesis (Xiao et al. 2013; Ta et al. 2016) . In contrast, the role of astrocytes is not clear yet, probably because of the conflicting results of the previous studies (Duffy et al. 2014) .
Evidence for an exacerbating role of astrocytes has been demonstrated by studies, using transgenic mice with inactivated astroglial nuclear factor-kappa B (NF-jB) (Brambilla et al. 2012 (Brambilla et al. , 2014 . The inhibition of astroglial NF-jB improved functional outcome in EAE, reduced the levels of expression of proinflammatory genes, and increased remyelination. In contrast, the loss of the astrocytic Fas ligand failed to induce the apoptosis of Fas + CD4 + T cells, or did not increase the number of Treg cells after EAE induction, which suggest a role of astrocytes in the control of autoreactive T cells in the neuroinflammatory conditions (Wang et al. 2013) . Furthermore, the inhibition of reactive astrogliosis in EAE enhanced the infiltration of myeloid cells and the severity of the disease (Toft-Hansen et al. 2011) . These results suggest that astrocytes play different roles in the pathology of MS/EAE. N-myc downstream-regulated gene 2 (Ndrg2) is a differentiation-and stress-associated gene and tumor-suppressor (Qu et al. 2002; Hu et al. 2016) . NDRG2 is a cytoplasmic protein that contains several phosphorylation sites (Murray et al. 2004) . Recent studies in adult T-cell leukemia/ lymphoma and other cancers have revealed that the loss of NDRG2 activates phosphatidylinositol 3-kinase (PI3K)-Akt and NF-jB signaling by recruiting protein phosphatase 2A (Nakahata et al. 2014; Ichikawa et al. 2015) . Our group and others have demonstrated that NDRG2 is primarily expressed in astrocytes in the CNS (Nichols 2003; Okuda et al. 2008; Takeichi et al. 2011) , and functions as a positive regulator of reactive astrogliosis in the early phase following brain injury (Takarada-Iemata et al. 2014) . Deletion of Ndrg2 attenuated the hypertrophic changes of astrocytes and accumulation of microglia after cortical injury. Compared with wild-type (WT) mice, Ndrg2 À/À mice showed decreased expression of cytokines in the interleukine-6 family and decreased activation of signal transducer and activator of transcription 3. These lines of evidence suggest that NDRG2 is involved in the pathogenesis of neuroinflammation.
In this study, we sought to investigate the role of NDRG2 in EAE pathology. The expression of NDRG2 was observed in astrocytes in both the gray and white matter of the spinal cord under physiological conditions, and it was enhanced after EAE induction. Deletion of Ndrg2 ameliorated the clinical symptoms of EAE. Although Ndrg2 deficiency only slightly affected the inflammation, it significantly reduced demyelination in the chronic phase, and, more importantly, neurodegeneration both in the acute and chronic phases of EAE. Further studies revealed that the expression levels of glutamate transporters, including glutamate aspartate transporter (GLAST) and glutamate transporter 1 (GLT-1), were higher in Ndrg2 À/À mice compared with WT mice after EAE induction. Similarly, in cultured astrocytes, the gene silencing of Ndrg2 increased the expression of GLAST, while the over-expression of NDRG2 decreased it, which may be associated with the activation of Akt. These results suggest that NDRG2 play a key role in the pathology of EAE by modulating glutamate metabolism.
Materials and methods

Mice and induction of EAE
All animal experiments were approved by the Animal Care and Use Committee of Kanazawa University (AP-143307). The Ndrg2 À/À mice were generated as previously described (Takarada-Iemata et al. 2014) , and backcrossed with the C57BL/6N strain (Japan SLC Inc., Hamamatsu, Shizuoka, Japan) (RRID:IMSR_CRL:27) over more than eight generations. The mice were housed in a temperature-and humidity-controlled environment under a 12-h light-dark cycle. This study was not pre-registered. Male WT and Ndrg2 À/À mice (age 7-10 weeks; weight 20-25 g)
were used for the experiments. No randomization was performed because relatively small numbers of mice (3-6 mice per genotype) were used in each set of experiment. EAE was induced as previously described (Ta et al. 2016) .In brief, 100 lL of an emulsion of Complete Freund's Adjuvant (Chondrex, Inc., Redmond, WA, USA) and 100 lg of myelin oligodendrocyte glycoprotein peptide 35-55 [GL Biochem (Shanghai) Ltd., Shanghai, China] was subcutaneously injected into two sites (total 200 lL) in the backs of the mice. At 0 and 48 h after immunization, the mice were intraperitoneally injected with 400 ng/mouse of pertussis toxin (List Biological Laboratories, Inc., Campbell, CA, USA). After EAE induction, samples from the acute and chronic phases were taken between days 14 and 17 and after day 30, respectively. The mice were monitored daily for clinical severity, as previously described (Miller et al. 2010) , according to the following standard (0-5) EAE grading scale: 0, normal; 1, limp tail or hind limb weakness, but not both; 2, limp tail and hind limb weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis; and 5, moribund or death by EAE. The data were excluded if mice died during the EAE course. No blinding was performed.
Western blotting
Samples from cultured cells or the lumbar spinal cords of the mice were solubilized in buffer containing 10 mM Tris (pH 7.6), 1 mM EDTA, 150 mM NaCl,1% NP-40, 0.1% sodium dodecyl sulfate, 0.2% sodium deoxycholate, 1 mM phenylmethylsulfonyl flouride, 1 lg/mL aprotinin, 10 mM NaF, and 1 mM Na3V4. The solubilized samples were subjected to western blotting with the following antibodies: NDRG2 
Immunohistochemistry
The lumbar spinal cords (L1-L5) were dissected from the mice after they were perfused with 4% paraformaldehyde, and they were then cut into 10-lm-thick cross-sections were cut on a cryostat. The sections were processed for immunohistochemistry with the following antibodies: NDRG2 Isolation of the mononuclear cells from the tissue Mononuclear cells from the spleen and lymph nodes were prepared by homogenizing the tissue through a cell strainer (BD), and then treating them with an ammonium-chloride-potassium lysing buffer (Thermo Fisher Scientific Inc.). Mononuclear cells from the brain and spinal cord were isolated as previously described (Schattling et al. 2012) . In brief, the mice were perfused with cold Hanks' Balanced Salt Solution, and the brains and spinal cords were removed. They were minced and digested in collagenase solution (Sigma-Aldrich Co. LLC) containing DNAse I (Sigma-Aldrich Co. LLC) for 45 min at 37°C. After triturating through the cell strainer (BD), the tissue was resuspended in 30% Percoll (GE Healthcare Bio-Sciences) and layered underneath 70% Percoll. After centrifugation (1500 g, 30 min), the cells were harvested from the interface.
Flow cytometry
The cells were incubated with anti-CD16/32 (FcR block; BioLegend, RRID:AB_2561482) on ice for 15 min to prevent nonspecific staining and then subsequently stained for 45 min at 4°C with one of the following: PE-anti-B220 (1 : 100; BioLegend, RRID:AB_312992), FITC-CD45 (1 : 100; BioLegend, RRID: AB_312972), PE/Cy7-anti-CD4 (1 : 100; BioLegend, RRID: AB_312707), PE-anti-IFNc (XMG1.2, 1 : 100; BioLegend), eFluor660-anti-IL-17A (eBio17BT, 1 : 100; eBioscience, San Diego, CA, USA), APC-anti-CD25 (PC61, 1 : 100; BioLegend, AB_ 2280288), PE-anti-Foxp3 (1 : 100; eBioscience, RRID:AB_465935), APC-anti-CD8a (1 : 100; eBioscience, RRID:AB_469334) and BV510-anti-CD11b (1 : 100; BioLegend, RRID:AB_2561390).
The flow cytometry was performed using the Gallios TM flow cytometer (Beckman Coulter Inc., Indianapolis, IN, USA), and the data were analyzed, using the Kaluza software (Beckman Coulter Inc.).
Quantitative real time RT-PCR (qRT-PCR)
The mice were perfused intracardially with ice-cold phosphatebuffered saline, and their lumbar spinal cords (L1-L5) were collected. The excised segments were immediately stored at À80°C until RNA extraction. The total RNA from the lumbar spinal cords and cultured astrocytes was isolated, using RNeasyâ mini kit (QIAGEN Sciences, Germantown, MD, USA) and High Pure RNA Tissue Kit (Roche Diagnostics Corporation, Indianapolis, IN, USA), respectively. Reverse transcription reactions containing 1 lg of total RNA were performed, using PrimeScript TM (Takara Bio Inc., Otsu, Shiga, Japan). Individual cDNA was amplified with THUNDERBIRD TM SYBR qPCR â Mix (Toyobo Co, Ltd., Osaka, Japan), using specific primers for Ccl2, Ccl5, Ccl7, Cdh2, Cxcl9, Cxcl10, Icam1, Il1b, Il6, Il17a, Ifng, Nos2, Tnf, Tgfb1, Vcam1, and Gapdh. The primer sequences are listed in Table S1 . The comparative Ct method was used for the data analyses with MxPro 4.10 (Agilent Technologies Inc.). The values of each gene were normalized to the Gapdh expression levels.
Cell culture
Astrocytes were isolated from the cerebral cortex of 1-3d-old neonatal mice, according to a previously described method with minor modifications (McCarthy and de Vellis 1980). We employed this method to obtain a relatively large number of astrocytes enough for all experiments. Briefly, the cerebral hemispheres were harvested from the neonatal mice, and the meninges were carefully removed. The brain tissue was then digested at 37°C in HEPES-buffered saline containing Dispase II (2 mg/mL; Wako Pure Chemical Industries, Ltd.). The cells were resuspended in Dulbecco's Modified Eagle's medium (Sigma-Aldrich Co. LLC) supplemented with 10% fetal bovine serum (Sigma-Aldrich Co. LLC) and an antibiotic mixture [penicillin (50 lg/mL) and streptomycin (100 lg/ mL)], and plated in T75 culture flasks (Corning Inc., Corning, NY, USA) at a density of three brains/flask. After a 12-14 day cultivation period, the astrocytes were separated by shaking (200 rpm, 2-8 h) and then plated at a density of 5 9 10 5 cells/ well in 6-well culture plates (western blot) or 12-well culture plates (qRT-PCR). The isolated astrocytes were used in the experiments after they reached full confluency.
RNA interference
The RNA interference of NDRG2 was performed as previously described (Takeichi et al. 2011) . In brief, the NDRG2-specific siRNAs, NDRG2-siRNA1 and NDRG2-siRNA2 and control-siRNA were all obtained from Thermo Fisher Scientific Inc. Mixtures of NDRG2-siRNA1 and NDRG2-siRNA2 or control-siRNA were transfected into astrocytes by Lipofectamine RNAiMAX (Thermo Fisher Scientific Inc.) under the reverse transfection protocol according to the manufacturer's specifications. Sixteen hour after the transfection, the culture medium was replaced with fresh medium, and the cells were incubated another 48 h. In some cases, the cells were treated with the PI3K/Akt inhibitor, LY294002, for 1 h, which was followed by incubation with medium alone for another 48 h.
Recombinant adenovirus vectors
The recombinant adenovirus vector AxCALNLZ2-NDRG2 (Ad-NDRG2) was constructed as previously described (Takeichi et al. 2011) . The viral stocks had titers of~1 9 10 8 plaque-forming units/ mL. The Cre-recombinase-expressing adenovirus vector AxCANCre, which was used to examine the regulation the regulation of NDRG2 expression, and the control virus vector AxCALNLZ2 LacZ (b-Galactosidase) were similarly prepared similarly (Takarada-Iemata et al. 2014). The cultured astrocytes were infected with either the Ndrg2-expressing adenovirus vector (Ad-NDRG2) or the control adenovirus vector (Ad-LacZ), in which the gene expression was controlled by the Cre-loxP system. Sixteen h after infection, the culture medium was replaced with the fresh medium, and the cells were incubated another 48 h.
Statistical analyses
All results are expressed as mean AE standard error of the mean. Mann-Whitney U-tests, Wilcoxon signed-rank tests or analyses of variance with the Bonferroni/Dunnett post hoc tests were performed to determine statistical significance, using Statcel3 (OMS publishing Inc., Tokorozawa, Saitama, Japan). An assessment of normality of the data was carried out using Kolmogorov-Smirnov test. P values less than 0.05 were considered significant. No sample calculation was performed.
Results
Expression of NDRG2 after EAE induction
First, we evaluated the levels of expression of NDRG2 under physiological and EAE conditions. Western blot analysis revealed that the NDRG2 expression levels were significantly increased in both the acute and chronic periods after EAE induction (Fig. 1a) , when the levels of GFAP, which is the most commonly used marker of activated astrocytes, were also increased (see Fig. 4a and b) . To further investigate the distribution of NDRG2 in the spinal cord in the physiological (control) and pathological (EAE) conditions, the immunohistochemical analysis was performed (Fig. 1b  and c) . Consistent with previous findings in the brain (Nichols 2003; Okuda et al. 2008; Takeichi et al. 2011) , NDRG2 was expressed in astrocytes in both conditions ( Fig. 1b and c) . We did not observe NDRG2 expression in CD45 + -infiltrating immune cells or other types of CNSresident cells, including neurons, microglia, or oligodendrocytes (Fig. 1c) . The expression of NDRG2 was observed in both protoplasmic (gray matter) and fibrous (white matter) astrocytes in the physiological condition, and its expression was enhanced after EAE induction (Fig. 1b , high magnification). However, in some regions such as the surface of the spinal cord, the expression of NDRG2 was low, compared to that of GFAP (Fig. 1b, low magnification) .
The effects of Ndrg2 deficiency on EAE severity and demyelination To investigate whether NDRG2 plays a role in the pathology of EAE, we compared the phenotypes of WT and Ndrg2 À/À mice before and after the induction of EAE. In the physiological condition, there were no gross differences between the WT and Ndrg2 À/À mice in the spinal cord (Fig. S1a) , 2.1 AE 0.1) (Fig. 2a) . Consistent with these results, immunohistochemical analysis revealed that the demyelination in Ndrg2 À/À mice had only tendency to be lower than that in WT mice in the acute phase, while it was significantly lower in the chronic phase after EAE induction (Fig. 2b) . Furthermore, the number of (Fig. 3a) . Furthermore, the numbers of T H 1 (IFN (Fig. S2) . Only the number of CD8 + T cells was lower in the Ndrg2 À/À mice than in the WT mice (Fig. 3a) . Consistent with these results, the production of cytokines, chemokines and other inflammation mediators did not differ between the genotypes in both the acute (Fig. S3 ) and chronic phases (Fig. S4 ) except for the production of Vcam, which was slightly lower in Ndrg2 À/À mice in the acute EAE period (Fig. S3 ).
Immunohistochemical analysis revealed that the infiltration of CD45 + cells was similar in both genotypes in the acute EAE phase (Fig. 3b) .
To further analyze whether deletion of (Fig. S6) .
The effects of Ndrg2 deficiency on glial activation and neurodegeneration after EAE induction Although EAE is mediated by activated CD4 + cells, ample evidence has demonstrated that gliosis and neurodegeneration are also critical in EAE pathology, and their levels correlate with demyelination and clinical severity after EAE induction (Wang et al. 2005; Duffy et al. 2014) . Therefore, we compared the activation statuses of glial cells and the damages to neuronal cells between the genotypes after EAE induction. Western blot analysis revealed that the levels of expression of activated glial markers, such as GFAP (astrocytes) and Iba1 (microglia), were enhanced similarly in both genotypes in the acute phase of EAE (Fig. 4a) . In the chronic phase, the expression of GFAP tended to be lower in Ndrg2 À/À mice, while that of Iba1 was similar in both genotypes (Fig. 4b) . In contrast to the glial markers, the expression of a neuronal marker NeuN was decreased during EAE, but the amount of decrease was smaller in Ndrg2 À/À mice, compared with WT mice in both the acute and chronic phases ( Fig. 4a and b) . Consistently, immunohistochemical analysis revealed that the number of ATF3 + /ChAT + cells (damaged motor neurons) in the acute phase (Fig. 5a ) and the number of ATF3 + /Nissl + cells (damaged neurons) in the acute and chronic phases of EAE (Fig. S7) were lower in Ndrg2 À/À mice. Furthermore, the expression of SMI32
(damaged axons in the white matter), typically in the swollen or irregularly shaped axons (Trapp et al. 1998; Wang et al. 2005) , was more prominent in WT mice than in Ndrg2 À/À mice in both the acute and chronic phases after EAE induction (Fig. 5b) .
The effects of Ndrg2 deficiency on the expression of glutamate transporters after EAE Previous studies have demonstrated that the expression of glutamate transporters, such as GLAST and GLT-1, in astrocytes was reduced in EAE (Ohgoh et al. 2002; Ramos et al. 2010) , which suggests that glutamate toxicity plays an important role in the pathogenesis of MS/EAE (Ramos et al. 2010; Macrez et al. 2016) . Therefore, we assessed the expression levels of both glutamate transporters in our model. Western blot analysis revealed that the levels of expression of GLAST and GLT-1 proteins did not differ significantly between the genotypes in the physiological condition (Fig. 6a) . However, after EAE induction, the levels of expression of both proteins were reduced in WT mice, while they were somehow maintained in Ndrg2 À/À mice (Fig. 6a) . Interestingly, this phenotype was observed in Ndrg2 À/À mice when the levels of GFAP expression did not differ between the genotypes (Fig. 4a) , which suggested that this was not simply due to different levels of glial activation in the two genotypes. Furthermore, immunohistochemical analysis revealed that both GLAST and GLT-1 were partly co-localized with NDRG2 in both the control and EAE conditions (Fig. 6b) , but GLAST and GLT-1 were more prominent in the processes than in the cytosol. À/À mice were subjected to immunohistochemistry for glutamate aspartate transporter (GLAST) or glutamate transporter 1 (GLT-1) (green) and N-myc downstream-regulated gene 2 (NDRG2) (red). Scale bars: 10 lm. WT mice (N = 7; number of mice) and Ndrg2 À/À mice (N = 7; number of mice) from three independent experiments were analyzed. 
The effects of Ndrg2 on the expression of glutamate transporters and signaling pathways To examine whether the effects of Ndrg2 deletion on the astrocytic glutamate transporters were direct or indirect through the milder phenotype of EAE, gene silencing and over-expression experiments were performed, using cultured mouse astrocytes. Consistent with the finding of our previous reports (Takeichi et al. 2011; Takarada-Iemata et al. 2014) , western blot analysis revealed that silencing of Ndrg2 almost completely abolished the NDRG2 expression (Fig. 7a) , while adenovirus vector-mediated over-expression of NDRG2 enhanced the expression of NDRG2 (Fig. 7b) . The expression of GLAST was enhanced by Ndrg2 silencing (Fig. 7a ) and reduced by Ndrg2 over-expression (Fig. 7b) . Because the expression of GLT-1 was very low in the cultured astrocytes, as has been previously described (Lin et al. 2014) , we focused on the analysis of GLAST expression in this study. In all conditions, the expression of GFAP did not differ significantly between the genotypes ( Fig. 7a and b) . Because the loss of NDRG2 has been reported to activate several signaling pathways such as Akt (Nakahata et al. 2014) and NF-jB (Ichikawa et al. 2015) , we evaluated the activation status of these molecules. Western blot analysis revealed that the silencing of Ndrg2 enhanced the expression of the phosphorylated forms of Akt (p-Akt), but not that of NF-jB p65 (p-p65) (Fig. 7c) . To investigate the effects of Akt activation on the GLAST expression, cultured astrocytes transfected with Control-or NDRG2-siRNA were treated with LY294002, an inhibitor of PI3K/Akt, and the levels of GLAST expression were analyzed. Treatment with LY294002 canceled the effects of the silencing of Ndrg2 on GLAST expression (Fig. 7d) .
To confirm the activation status of the signaling pathways in vivo, western blot was performed using samples from lumber spinal cord (Fig. 7e) . The expression of p-Akt, but not other molecules, such as p-p65, p-p38, and p-ERK, was reduced after EAE induction in WT mice. However, the levels of expression were higher in Ndrg2 À/À m`ice, which suggested that the Akt-signaling pathways were more activated in Ndrg2 À/À mice in vivo.
Discussion
In this study, we investigated the expression and role of NDRG2 in EAE. The expression of NDRG2 was exclusively observed in astrocytes of the spinal cord, and the expression was enhanced after EAE induction. Analysis of WT and Ndrg2 À/À mice revealed that NDRG2-expressing astrocytes had detrimental effects on neurons in both the acute and chronic phases of EAE, and on oligodendrocytes in the chronic phase of EAE. In contrast, NDRG2-expressing astrocytes had small, if any, effects on the infiltration and inflammatory responses of immune cells after EAE induction. Additional studies revealed that deletion of Ndrg2 restored the EAE-related decreases in the expression of the astrocytic glutamate transporters, including GLAST and GLT-1. The enhancing and reducing effects of NDRG2 on GLAST expression were also observed in the cultured systems, when Ndrg2 gene was silenced and over-expressed, respectively, at least partly through the activation of the Akt signaling pathway. As discussed in the introduction, both protecting and exacerbating roles of astrocytes have been demonstrated in MS/EAE. Transgenic mice with inactivated astroglial NF-jB have been developed, and used to study the exacerbating roles of astrocytes (Brambilla et al. 2012 (Brambilla et al. , 2014 . WT and transgenic mice developed similar pattern of EAE pathology during the acute phase, but the transgenic mice exhibited lower levels of immune cell infiltration and proinflammatory gene expression and increased remyelination in the chronic phase. In our model, in contrast, milder phenotypes of clinical symptoms and neurodegeneration were observed in both the acute and chronic phases in Ndrg2 À/À mice after EAE induction, while the infiltration of immune cells and expression of proinflammatory genes were at similar levels in WT and Ndrg2 À/À mice except the lower number of CD8 + cells in the Ndrg2 À/À CNS after EAE (Fig. 3a) . Although astrocytes may influence the proliferation of CD8 + cells in IFNc-dependent or -independent manner (Cornet et al. 2000) , the roles of CD8 + cells in the EAE pathology are still highly debated (Camara et al. 2013; Leuenberger et al. 2013; Luo et al. 2014) . Further studies are required to clarify Fig. 7 Expression of the glutamate transporters and activation of Akt in Ndrg2 silenced/deleted conditions. Gene silencing (a, c and d) and overexpression of Ndrg2 (b). Cultured mouse astrocytes were transfected with either control siRNA or N-myc downstream-regulated gene 2 (NDRG2) siRNA (a, c and d), or infected with Ndrg2-expressing adenovirus vector or adenovirus vector alone (b). The cells were cultured for 3 days after siRNA transfection or adenovirus vector infection, and lysed in RIPA buffer. The cell lysates were then subjected to western blotting with the indicated antibodies. In (d) the cells were cultured for 2 days after siRNA transfection, treated with LY29004 (20 lM) for 1 h, and harvested after 24 h. The cells were lysed in RIPA and subjected to western blotting with glutamate aspartate transporter (GLAST) and NDRG2. The values shown represent the mean AE SEM (N = 6; number of cells prepared from three independent experiments). *p < 0.05, **p < 0.01 compared to controls, Wilcoxon signed-ranks test. (e) activation status of the signaling pathways after EAE induction. EAE was induced in wild-type (WT) and Ndrg2 À/À mice, and protein samples that were extracted from the lumbar spinal cord were subjected to western blotting for the indicated proteins. Typical results, using protein samples from WT mice (acute EAE N = 6, control N = 6; number of mice) and Ndrg2 À/À mice (acute EAE N = 6, control N = 6; number of mice) from two independent experiments) are shown. The values presented are the mean AE SEM. *p < 0.05 compared to controls, MannWhitney U-test.
the possible involvement of CD8 + cells-mediated inflammatory response in our models.
Accumulating evidence suggests that glutamate toxicity plays a pathogenic role in MS/EAE (Macrez et al. 2016) . In addition to its well-established toxic effects on neurons, glutamate can induce cell damage or malfunctioning of different types of cells including oligodendrocytes and astrocytes (Ohgoh et al. 2002; Matute 2011) . Consistently, the spinal up-regulation of the glutamate transporter GLT-1 improved the severity of EAE (Ramos et al. 2010 ). In our model, Ndrg2 À/À mice demonstrated milder EAE phenotypes in several aspects, including mild neurodegeneration in both the soma and axon, reduced demyelination, and the improved expression of astroglial glutamate transporters after EAE induction. While MS is generally considered a white matter disease with pathology characterized by inflammation, glial activation, and demyelination, the gray matter has also been reported to be the place to be affected, even during the earliest phases of the disease. The gray matter pathology may result from both inflammatory and neurodegenerative mechanisms, that include glutamate toxicity (Calabrese et al. 2015) . Our results suggest that NDRG2 enhances neurodegeneration in both the white and gray matter through the impairment of glutamate homeostasis after EAE induction. In addition, we speculate that the milder demyelination in the chronic Ndrg2 À/À mice (Fig. 2b ) may also be associated with altered glutamate homeostasis, as previously described (Matute 2011) . In cultured astrocytes, the gene silencing of Ndrg2 enhanced the expression of GLAST and the activation of Akt but not that of NF-jB p65. Furthermore, the inhibition of PI3K/Akt with LY294002 canceled the Ndrg2 silencingassociated enhancement of GLAST expression (Fig. 7d) . In the EAE mice, the levels of p-Akt were decreased in WT mice but preserved in Ndrg2 À/À mice, which suggest that NDRG2 plays roles in Akt-signaling pathway and glutamate transporters in vitro and in vivo. Akt signaling pathway was reported to play a critical role in maintaining the expression of GLAST (Lin et al. 2014) and GLT-1 (Zhang et al. 2013) in pathological conditions. Our results were consistent with a recent report that showed that the loss of NDRG2 expression activated PI3K/Akt signaling in cancer cells (Nakahata et al. 2014) . However, to the best of our knowledge, this is the first report to demonstrate the role of NDRG2 in Akt activation and glutamate transporters in astrocytes and neuroinflammatory conditions. We previously reported that deletion of Ndrg2 led to the reduced level of astroglial activation after brain injury (Takarada-Iemata et al. 2014) . In this study, however, we observed the improved level of expression of astrocytic glutamate transporters and milder neurodegeneration in Ndrg2 À/À mice in the acute phase of EAE, when there was no significant difference in the expression of GFAP between the two genotypes (Fig. 4a) . This discrepancy suggests that NDRG2 may modulate several signaling pathways such as signal transducer and activator of transcription 3, Akt and NF-jB, depending on the conditions, which affect the astroglial activation in different ways. Therefore, it will be important to investigate the molecular mechanism for the involvement of NDRG2 in each signaling pathway. Recently, two types of activated astrocytes, harmful A1 and protective A2 have been proposed in line with the M1/ M2 macrophage nomenclature (Liddelow et al. 2017) . A1 astrocytes up-regulate many classical complement cascade genes that are destructive to synapses, while A2 astrocytes up-regulate many neurotrophic factors (Zamanian et al. 2012; Liddelow et al. 2017) . Interestingly, a marker of A1 astrocytes, complement component 3 (C3), is highly expressed in human neuroinflammatory and neurodegenerative diseases including MS. Therefore, analysis of A1 and A2 astrocytes in our model would be quite intriguing.
In conclusion, we have demonstrated that, in EAE, NDRG2 plays a pathological role that is associated with the expression of glutamate transporters through the PI3K/ Akt signaling pathway. NDRG2-expressing astrocytes could be a novel target for regulating neurodegeneration and demyelination in neuroinflammatory conditions.
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